+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Triamcinolone acetonide in Transfersomes induces less skin atrophy than an equipotent dosage of a commercial drug formulation



Triamcinolone acetonide in Transfersomes induces less skin atrophy than an equipotent dosage of a commercial drug formulation



Journal of Investigative Dermatology 115(3): 589




(PDF emailed within 1 workday: $29.90)

Accession: 035985945

Download citation: RISBibTeXText


Related references

Improved risk-benefit ratio for a triamcinolone acetonide Transfersomes formulation in comparison to a commercial triamcinolone acetonide formulation. Journal of Investigative Dermatology 115(3): 590, 2000

Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes. Biochimica et Biophysica Acta 1614(2): 156-164, 2003

Double-blind, dose-ranging multicentre paediatric study to compare the efficacy of a chlorofluorocarbon formulation of trimacinolone acetonide and a CFC-free formulation of triamcinolone acetonide. European Respiratory Journal Supplement 10(25): 221S, Sept, 1997

Activity of a triamcinolone acetonide/laurocapram formulation: Double-blind comparisons with triamcinolone acetonide, placebo vehicle, and mid-strength (Class IV) to potent (Class II) corticosteroids. Current Therapeutic Research 62(3): 180-186, 2001

Activity of a 0.05% triamcinolone acetonide/laurocapram formulation: Double-blind, randomized comparison with standard 0.1% triamcinolone acetonide creams and with mild (class VI) to potent (class III) topical corticosteroids. Current Therapeutic Research 62(4): 231-235, 2001

Simultaneous determination of triamcinolone acetonide palmitate and triamcinolone acetonide in beagle dog plasma by UPLC-MS/MS and its application to a long-term pharmacokinetic study of triamcinolone acetonide palmitate lipid emulsion injection. Journal of Pharmaceutical and Biomedical Analysis 104: 105-111, 2015

Development and regression of dermal corticosteroid atrophy. 4. Concentration dependence of the skin thinning effect of triamcinolone acetonide. Dermatosen in Beruf und Umwelt. Occupation and Environment 35(2): 55-57, 1987

A study of the activity and tolerability of a dermatological formulation of triamcinolone acetonide and nystatin in candida albicans induced skin pathology. Clinica Terapeutica 123(5): 363-368, 1987

Determination of triamcinolone, triamcinolone acetonide and fluocinonide in dosage forms. Acta Poloniae Pharmaceutica 47(1-2): 15-17, 1990

Comparison of the systemic effects of fluticasone propionate and triamcinolone acetonide administered in equipotent doses in children with asthma. Pediatric Asthma Allergy & Immunology 16(4): 283-293, Winter, 2003

Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial. British Journal of Dermatology 149(3): 611-619, 2003

Nonpigmenting solitary fixed drug eruption after skin testing and intra-articular injection of triamcinolone acetonide. Annals of Allergy, Asthma and Immunology 86(3): 335-336, 2001

Determination of triamcinolone acetonide in silicone oil and aqueous humor of vitrectomized rabbits' eyes: Application for a pharmacokinetic study with intravitreal triamcinolone acetonide injections (KenalogĀ® 40). Journal of Pharmaceutical and Biomedical Analysis 89: 24-27, 2014

Spectrophotometric estimation of triamcinolone acetonide in its dosage forms. Indian Drugs 24(1): 59-61, 1986

Spectrophotometric estimation of triamcinolone acetonide in its dosage form. Indian Drugs 22(9): 489-490, 1985